Smoking Addiction in Patients with Schizophrenia Spectrum Disorders and Its Perception and Intervention in Healthcare Personnel Assigned to Psycho-Rehabilitation Programs: A Qualitative Research.

e-cigarette healthcare personnel qualitative research schizophrenia smoking addiction

Journal

Healthcare (Basel, Switzerland)
ISSN: 2227-9032
Titre abrégé: Healthcare (Basel)
Pays: Switzerland
ID NLM: 101666525

Informations de publication

Date de publication:
13 Nov 2022
Historique:
received: 15 10 2022
revised: 05 11 2022
accepted: 07 11 2022
entrez: 24 11 2022
pubmed: 25 11 2022
medline: 25 11 2022
Statut: epublish

Résumé

Patients with schizophrenia spectrum disorders have a higher prevalence and frequency of smoking rates when compared to the rest of the population; to this, it must be added that they develop a greater dependence and have some worse health consequences than the general population. This is qualitative research on the perception of smoking in healthcare professionals assigned to psycho-rehabilitation programs for patients with schizophrenia spectrum disorders. The point of view of health personnel (Psychologists, Psychiatrists, Pedagogists, and Nurses) about cigarette smoking in these patients was analyzed, focusing on their implications in disturbance and comparing them with e-cigarettes too. The methodology used to collect the data was a semi-structured interview with five questions. The research path was carried out in two assisted therapeutic communities that are clinics for the rehabilitation of serious mental illness in the period between November and July 2022. The results showed that the opinion of health professionals on smoking is very negative. Research has also shown that nearly all patients are smokers; however, their high grade of addiction is caused by periods of high stress due to various factors that lead patients to consume a greater number of cigarettes. Almost all respondents have a positive opinion of the e-cigarette, which was defined as an excellent substitute for traditional cigarettes.

Identifiants

pubmed: 36421599
pii: healthcare10112275
doi: 10.3390/healthcare10112275
pmc: PMC9690727
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Int J Psychiatry Med. 2010;40(3):247-57
pubmed: 21166336
Schizophr Res. 2004 Dec 15;72(1):29-39
pubmed: 15531405
J Psychiatr Res. 2014 Jan;48(1):102-10
pubmed: 24139811
J Gen Intern Med. 2021 Dec;36(12):3888-3890
pubmed: 32875504
Schizophr Res. 2004 Jun 1;68(2-3):283-97
pubmed: 15099610
Drug Alcohol Depend. 2018 Oct 1;191:234-258
pubmed: 30153606
Lancet. 2018 Nov 10;392(10159):1789-1858
pubmed: 30496104
Neuropharmacology. 2012 Mar;62(3):1564-73
pubmed: 21288470
Arch Gen Psychiatry. 2005 Jun;62(6):649-59
pubmed: 15939842
Addict Behav Rep. 2017 Jan 24;5:67-84
pubmed: 29450229
Prog Neuropsychopharmacol Biol Psychiatry. 2019 Jun 8;92:476-482
pubmed: 30794823
BMJ Open. 2014 Mar 04;4(3):e004216
pubmed: 24595134
JAMA Psychiatry. 2014 Mar;71(3):248-54
pubmed: 24382686
Biol Psychiatry. 2013 Sep 15;74(6):436-43
pubmed: 23660272
Health Psychol Res. 2020 May 26;8(1):8652
pubmed: 32529090
Psychiatr Danub. 2009 Sep;21(3):371-5
pubmed: 19794359
Neurosci Biobehav Rev. 2005;29(6):1021-34
pubmed: 15964073
Psychol Addict Behav. 2003 Dec;17(4):259-65
pubmed: 14640821
Int J Environ Res Public Health. 2021 Jul 21;18(14):
pubmed: 34300168
JAMA Netw Open. 2022 Apr 1;5(4):e226692
pubmed: 35426926
J Psychiatr Res. 2014 Mar;50:84-91
pubmed: 24373929
JAMA Psychiatry. 2015 Dec;72(12):1172-81
pubmed: 26509694
Psychopharmacology (Berl). 2008 Jul;199(1):89-98
pubmed: 18548234
Am J Psychiatry. 2006 Nov;163(11):1877
pubmed: 17074936
Biol Psychiatry. 2017 Jan 1;81(1):9-20
pubmed: 27720198
Schizophr Res. 2015 Apr;163(1-3):24-31
pubmed: 25248939
BMJ. 1994 Jan 1;308(6920):21-6
pubmed: 8179658
Br J Psychiatry. 2017 Sep;211(3):175-181
pubmed: 28684403
Appl Neuropsychol Adult. 2017 Jan-Feb;24(1):50-64
pubmed: 26980544
Curr Drug Abuse Rev. 2008 Nov;1(3):328-39
pubmed: 19630729
Psychiatry Res. 2019 Feb;272:155-163
pubmed: 30583258
J Clin Psychiatry. 2005 Nov;66(11):1447-55
pubmed: 16420083
Schizophr Res. 2016 Mar;171(1-3):1-15
pubmed: 26803692
J Clin Psychiatry. 2012 Apr;73(4):468-75
pubmed: 22579146
Br J Psychiatry. 2005 Mar;186:215-21
pubmed: 15738502
Neuropharmacology. 2012 Mar;62(3):1371-80
pubmed: 21420988

Auteurs

Pasquale Caponnetto (P)

Department of Educational Sciences, Section of Psychology, University of Catania, 95121 Catania, Italy.
Center of Excellence for the Acceleration of Harm Reduction (COEHAR), University of Catania, 95121 Catania, Italy.

Marilena Maglia (M)

Department of Educational Sciences, Section of Psychology, University of Catania, 95121 Catania, Italy.
CTA-Villa Chiara Psychiatric Rehabilitation Clinic and Research, 95030 Mascalucia, Italy.

Marta Mangione (M)

ECLAT Srl, Spin-Off of the University of Catania, 95121 Catania, Italy.

Chiara Vergopia (C)

Department of Educational Sciences, Section of Psychology, University of Catania, 95121 Catania, Italy.

Graziella Chiara Prezzavento (GC)

Department of Educational Sciences, Section of Psychology, University of Catania, 95121 Catania, Italy.

Riccardo Polosa (R)

Center of Excellence for the Acceleration of Harm Reduction (COEHAR), University of Catania, 95121 Catania, Italy.
Department of Clinical and Experimental Medicine, University of Catania, 95121 Catania, Italy.

Maria Catena Quattropani (MC)

Department of Educational Sciences, Section of Psychology, University of Catania, 95121 Catania, Italy.

Jennifer DiPiazza (J)

Hunter Bellevue School of Nursing, Hunter College, City University of New York, New York, NY 10065, USA.

Maria Salvina Signorelli (MS)

Department of Clinical and Experimental Medicine, University of Catania, 95121 Catania, Italy.

Classifications MeSH